Tumor Biology

, Volume 36, Issue 5, pp 3815–3822 | Cite as

Prognostic impact of polymorphism of matrix metalloproteinase-2 and metalloproteinase tissue inhibitor-2 promoters in breast cancer in Tunisia: case-control study

  • Dalel Ben Néjima
  • Yosr Ben Zarkouna
  • Amor Gammoudi
  • Mohamed Manai
  • Hamouda Boussen
Research Article


Matrix metalloproteinases (MMPs) are proteolytic enzymes that play important roles in tumor invasion and metastasis by degrading extracellular matrix components. Genetic variations in promoter regions of MMP genes, affecting their expression, have been associated with susceptibility to cancers. The aim of this study was to investigate the susceptibility and prognostic implications of the matrix metalloproteinase-2 (MMP-2) and tissue inhibitor of metalloproteinase-2 (TIMP-2) polymorphism in Tunisian breast cancer patients. MMP-2 genotypes were determined by real-time polymerase chain reaction (RT-PCR), and TIMP-2 genotypes were identified using a PCR-restriction fragment length polymorphism (RFLP) method in 210 breast cancer patients and 250 frequency-matched control women. Association of the clinicopathological parameters and the genetic markers with risk of breast cancer was assessed using univariate analyses. We found that the variant MMP-2 genotype (−1306CT or TT) was associated with substantially reduced risk of breast cancer [odds ratio (OR), 0.49; 95 % confidence interval (95 % CI), 0.033–0.73], compared with the CC genotype. For TIMP-2, a moderately reduced risk of the cancer (OR, 0.57; 95 % CI, 0.37–0.87) was also associated with the variant allele (−418GC or CC), compared with the GG common allele. Furthermore, polymorphisms in both genes seem to have additive effects and the highest risk for breast cancer has been observed in those with MMP-2 CC genotype and TIMP-2 GC or CC genotype (p = 0.006). A significant association was also found between the CC genotype and the aggressive forms of breast cancer as defined by advanced stages at the time of diagnosis and metastasis. This is the first report on the association of MMP-2 and TIMP-2 gene polymorphisms in breast cancer in Tunisian population. Our results suggest that the presence of the variant allele in the promoter of MMP-2 or TIMP-2 may be a protective factor for the development of breast cancer.


MMP Polymorphism Breast Cancer Susceptibility Invasion 


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMedGoogle Scholar
  2. 2.
    Kestler DP, Foster JS, Bruker CT, et al. ODAM expression inhibits human breast cancer tumorigenesis. Breast Cancer (Auckl). 2011;5:73–85.Google Scholar
  3. 3.
    Chouchane L, Boussen H, Sastry KS. Breast cancer in Arab populations: molecular characteristics and disease management implications. Lancet Oncol. 2013;14:e417–24.CrossRefPubMedGoogle Scholar
  4. 4.
    Yadav L, Puri N, Rastogi V, Satpute P, Ahmad R, Kaur G. Matrix metalloproteinases and cancer—roles in threat and therapy. Asian Pac J Cancer Prev. 2014;15(3):1085–91.CrossRefPubMedGoogle Scholar
  5. 5.
    Radisky ES, Radisky DC. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 2010;15:201–12.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549–58.CrossRefPubMedGoogle Scholar
  7. 7.
    Hajitou A, Sounni NE, Devy L, et al. Down-regulation of vascular endothelial growth factor by tissue inhibitor of metalloproteinase-2: effect on in vivo mammary tumor growth and angiogenesis. Cancer Res. 2001;61:3450–7.PubMedGoogle Scholar
  8. 8.
    Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman Jr RA, Kallakury BV. Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. Mod Pathol. 2003;16:198–205.CrossRefPubMedGoogle Scholar
  9. 9.
    Lambert E, Dasse E, Haye B, Petitfrere E. TIMPs as multifacial proteins. Crit Rev Oncol Hematol. 2004;49:187–98.CrossRefPubMedGoogle Scholar
  10. 10.
    Hirano K, Sakamoto T, Uchida Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J. 2001;18:748–52.CrossRefPubMedGoogle Scholar
  11. 11.
    Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci. 1977;74(12):5463–7.Google Scholar
  12. 12.
    Saeeed HM, Alanazi MS, Alshahrani O, Parine NR, Alabdulkarim HA, Shalaby MA. Matrix metalloproteinase-2 C(-1306)T promoter polymorphism and breast cancer risk in the Saudi population. Acta Biochim Pol. 2013;60:405–9.Google Scholar
  13. 13.
    Delgado-Encixso I, Cepeda-Lopez FR, Monrroy-Guizar EA, et al. Matrix metalloproteinase-2 promoter polymorphism is associated with breast cancer in a Mexican population. Gynecol Obstet Investig. 2008;65:68–72.CrossRefGoogle Scholar
  14. 14.
    Zhou Y, You C, Miao X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–404.CrossRefPubMedGoogle Scholar
  15. 15.
    Raoehe AV, Frazzon AP, Agnes G, Damin AP, Hartman AA, Graudenz MS. Detection of polymorphisms in the promoter of matrix metalloproteinase 2 and 9 genes in breast cancer in South Brazil: preliminary results. Breast Cancer Res Treat. 2007;102:123–4.CrossRefGoogle Scholar
  16. 16.
    Lei H, Hemminki K, Altieri A, et al. Promoter polymorphism in matrix metalloproteinases and their inhibitors: few associations with breast cancer susceptibility and progression. Breast Cancer Res Treat. 2007;103:61–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Beeghly-Fadiel A, Lu W, Long JR, et al. Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2009;18:1770–6.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Saeed HM, Alanazi MS, Parine NR, et al. Matrix metalloproteinase-2 (-1306C > T) promoter polymorphism and risk of colorectal cancer in the Saudi population. Asian Pac J Cancer Prev. 2013;14:6025–30.CrossRefPubMedGoogle Scholar
  19. 19.
    Xiaoping M, Chunyuan Y, Wen T, Ping X, Gang L, Wenfu L, et al. A functional polymorphism in the matrix metalloproteinase-2 gene promoter (-1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma. Cancer Res. 2003;63:3987–90.Google Scholar
  20. 20.
    Yifeng Z, Chunyuan Y, Xiaoping M, Wen T, Gang L, Ping X, et al. Substantial reduction in risk of breast cancer associated with genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes. Carcinogenesis. 2004;25:399–404.Google Scholar
  21. 21.
    Chunyuan Y, Kaifeng P, Deyin X, Gang L, Wen T, Lian Z, et al. Correlation between a single nucleotide polymorphism in the matrix metalloproteinase-2 promoter and risk of lung cancer. Cancer Res. 2002;62:6430–3.Google Scholar
  22. 22.
    Chunyuan Y, Yifeng Z, Xiaoping M, Ping X, Wen T, Dongxin L. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004;64:7622–8.CrossRefGoogle Scholar
  23. 23.
    Hirano K, Sakamoto T, Uchida Y, Morishima Y, Masuyama K, Ishii Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J. 2001;18:748–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Jiang Y, Goldberg ID, Shi YE. Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene. 2002;21:2245–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang M, Teng XD, Guo XX, Li ZG, Han JG, Yao L. Expression of tissue levels of matrix metalloproteinases and their inhibitors in breast cancer. Breast. 2013;22:330–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Wu CY, Wu MS, Chen CJ, et al. Clinicopathological significance of MMP2 and TIMP2 genotypes in gastric cancer. Eur J Cancer. 2007;43:799–808.CrossRefPubMedGoogle Scholar
  27. 27.
    Zagouri F, Sergentanis TN, Gazouli M, et al. MMP-2–1306 C > T polymorphism in breast cancer: a case-control study in a South European population. Mol Biol Rep. 2013;40:5035–40.CrossRefPubMedGoogle Scholar
  28. 28.
    Slattery ML, John E, Torres-Mejia G, et al. Matrix metalloproteinase genes are associated with breast cancer risk and survival: the Breast Cancer Health Disparities Study. PLoS One. 2013;8:63–5.CrossRefGoogle Scholar
  29. 29.
    Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89:1270–5.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Dalel Ben Néjima
    • 1
    • 2
  • Yosr Ben Zarkouna
    • 2
  • Amor Gammoudi
    • 3
  • Mohamed Manai
    • 1
  • Hamouda Boussen
    • 2
  1. 1.Unité de Biochimie et de Biologie Moléculaire 02/UR/09-04Faculté des Sciences de TunisTunisTunisia
  2. 2.Service d’Oncologie MédicaleHôpital Abderrahmen MamiArianaTunisia
  3. 3.Service d’AnatomopathologieInstitut Salah AzaiezTunisTunisia

Personalised recommendations